Undisclosed CLDN18.2 targeted masked TCE / Xilio Therap - LARVOL DELTA

Preclinical Data Presented at SITC (GlobeNewswire) - "...Xilio’s masked T cell engager molecules demonstrated potent anti-tumor activity with evidence of reduced systemic toxicity in murine models, supporting the broad applicability and potential best-in-class profile of Xilio’s masked T cell engager formats across a diverse range of targets. The incorporation of co-stimulatory signaling in Xilio’s proprietary SEECR format enhanced durability of anti-tumor activity compared with T cell engager molecules that lacked co-stimulation."

Preclinical • Solid Tumor

Anticipated Milestones for Masked T Cell Engager Programs (GlobeNewswire) - "Xilio nominated a development candidate for its PSMA program (ATACR format) in the third quarter of 2025 and anticipates nominating development candidates for its CLDN18.2 program (ATACR format) in the fourth quarter of 2025 and for its STEAP1 program (SEECR format) in the first half of 2026. Xilio anticipates advancing at least two of these programs into investigational new drug (IND) enabling studies and submitting IND applications for those programs in 2027."

IND • Pipeline update • Solid Tumor

Masked T Cell Engager Programs (GlobeNewswire) - "Xilio anticipates nominating development candidates for its PSMA program (ATACR format), CLDN18.2 program (ATACR format) and STEAP1 program (SEECR format) in the third quarter of 2025, fourth quarter of 2025 and first half of 2026, respectively; Xilio anticipates advancing at least two of these programs into initial IND-enabling studies and submitting IND applications for those programs in 2027."

IND • Pipeline update • Solid Tumor

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results (GlobeNewswire) - "Xilio anticipates nominating a development candidate for its CLDN18.2 program in the ATACR format in the fourth quarter of 2025 and submitting an IND application in the second quarter of 2027. CLDN18.2 has broad potential as a T cell engager target for gastric, pancreatic, esophageal and lung cancers."

IND • Esophageal Cancer • Gastric Cancer • Lung Cancer • Pancreatic Cancer

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs (GlobeNewswire) - "Xilio is currently advancing three wholly-owned preclinical programs for masked T cell engager molecules targeting the following tumor-associated antigens: PSMA, CLDN18.2 and STEAP1: Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 and submitting an investigational new drug application (IND) in the first quarter of 2027...CLDN18.2 program in the ATACR format in the fourth quarter of 2025 and submitting an IND in the second quarter of 2027...STEAP1 program in the SEECR format in the first half of 2026 and submitting an IND in the second half of 2027."

IND • Preclinical • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Lung Cancer • Pancreatic Cancer • Prostate Cancer